#USA #Tampa, Florida #neuroplastogens #Psilera #Magali Haas

Magali Haas Joins Psilera as Chief Medical Officer

Psilera, Inc., a prominent biopharmaceutical company specializing in neuropsychiatric disorders, has made a significant appointment by bringing in Magali Haas, MD/PhD, as its Chief Medical Officer. With a remarkable 25-year track record in pharmaceutical research and development, Dr. Haas is set to play a crucial role in advancing Psilera's pipeline of cutting-edge neuroplastogens into clinical development.

A New Chapter for Psilera

The addition of Dr. Haas signals a pivotal moment for Psilera, particularly as the company aims to enhance access to effective treatments for neuropsychiatric disorders. Dr. Chris Witowski, Co-Founder and CEO of Psilera, noted that her vast experience in converting innovative neuroscience research into FDA-approved medications aligns seamlessly with the company’s objectives.

"Her leadership is crucial as we gear up for what promises to be a transformative year for Psilera," emphasized Dr. Witowski.

Dr. Haas's Impressive Background

Dr. Haas has an extensive history leading successful global clinical trials, notably in Phase II and III studies. Her experience includes her founding role at Cohen Veterans Bioscience, combined with over ten years at Johnson & Johnson, where she held leadership positions that bridged bench research and clinical applications. This particular blend of expertise positions Dr. Haas as an ideal leader within Psilera, especially with the ongoing development of their main drug candidate, PSIL-006, and other critical assets aimed at treating neurological conditions.

Psilera's Ambitious Goals

Psilera is not resting on its laurels. Having recently established a licensing partnership with atai Life Sciences and secured a $2 million research grant from the National Institutes of Health (NIH), the company is poised for significant advancements in 2026. Dr. Haas’s expertise will bolster the company’s efforts to navigate the complex landscape of FDA approvals, ensuring that promising neuropsychiatric therapies reach the patients who desperately need them.

"I am exhilarated to work with such an innovative group, advancing treatments that could significantly improve the lives of those affected by debilitating brain disorders," stated Dr. Haas.

Pioneering Neuropsychiatric Therapies

Psilera's mission centers on delivering next-generation therapies for conditions such as depression and frontotemporal dementia (FTD). With PSIL-006 being a pioneering therapeutic option, the organization is committed to scientific excellence and a patient-centered approach. In bridging the gap between research and availability, Psilera aspires to cater to populations that have often gone underserved in terms of effective treatment options.

As the company gears up for the next stages of its development, the leadership of Dr. Haas stands out as a beacon of promise, navigating the landscape of neuropsychiatric medicine into new frontiers. Through innovative strategies and relentless pursuit of quality in treatment, Psilera is set to make a lasting impact in the field of neuropsychiatry, helping countless individuals cope with challenging brain disorders.

Conclusion

The appointment of Dr. Magali Haas as CMO is indeed a sign of Psilera’s unwavering commitment to pushing the boundaries of treatment for neuropsychiatric disorders. With her leadership and the company's dedication, there is genuine hope for the advancement of safe and effective therapies for those who need them most.